113 related articles for article (PubMed ID: 11730409)
1. Nonhypoglycemic effects of thiazolidinediones.
Quesada-Gómez JM; Serrano-Alferez I
Ann Intern Med; 2001 Dec; 135(11):1007-8. PubMed ID: 11730409
[No Abstract] [Full Text] [Related]
2. A comprehensive review of the antidiabetic agent rosiglitazone.
Glazer NB; Cheatham WW
Clin Ther; 2001 Feb; 23(2):307-8. PubMed ID: 11293563
[No Abstract] [Full Text] [Related]
3. New drug overview. Pioglitazone hydrochloride.
Am J Health Syst Pharm; 2000 Jan; 57(2):124-5. PubMed ID: 10688239
[No Abstract] [Full Text] [Related]
4. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.
Wooltorton E
CMAJ; 2002 Jan; 166(2):219. PubMed ID: 11826947
[No Abstract] [Full Text] [Related]
5. Nonhypoglycemic effects of thiazolidinediones.
Parulkar AA; Pendergrass ML; Granda-Ayala R; Lee TR; Fonseca VA
Ann Intern Med; 2001 Jan; 134(1):61-71. PubMed ID: 11187421
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
7. [Thiazolidinediones--a new class of oral antidiabetic drugs].
Jermendy G; Csermely P
Orv Hetil; 2001 Jul; 142(29):1547-54. PubMed ID: 11494746
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
9. [Pioglitazone].
Kobayashi M; Iwata M; Hiratani K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
[No Abstract] [Full Text] [Related]
10. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
11. Evidence that pioglitazone increases intracellular free magnesium concentration in freshly isolated rat adipocytes.
Nadler J; Scott S
Biochem Biophys Res Commun; 1994 Jul; 202(1):416-21. PubMed ID: 8037742
[TBL] [Abstract][Full Text] [Related]
12. [Rosiglitazone (BRL-49653)].
Oka Y
Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
[No Abstract] [Full Text] [Related]
13. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes.
van Harmelen V; Dicker A; Rydén M; Hauner H; Lönnqvist F; Näslund E; Arner P
Diabetes; 2002 Jul; 51(7):2029-36. PubMed ID: 12086930
[TBL] [Abstract][Full Text] [Related]
14. [Medication of the month. Rosiglitazone (Avandia)].
Scheen AJ
Rev Med Liege; 2002 Apr; 57(4):236-9. PubMed ID: 12073798
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.
Iwata M; Haruta T; Usui I; Takata Y; Takano A; Uno T; Kawahara J; Ueno E; Sasaoka T; Ishibashi O; Kobayashi M
Diabetes; 2001 May; 50(5):1083-92. PubMed ID: 11334412
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone (CS-045): a new antidiabetic agent.
Kaneko T
Horm Metab Res; 1997 May; 29(5):203-13. PubMed ID: 9228204
[No Abstract] [Full Text] [Related]
17. Rosiglitazone toxicity.
Ravinuthala RS; Nori U
Ann Intern Med; 2000 Oct; 133(8):658. PubMed ID: 11033603
[No Abstract] [Full Text] [Related]
18. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.
Rieusset J; Auwerx J; Vidal H
Biochem Biophys Res Commun; 1999 Nov; 265(1):265-71. PubMed ID: 10548525
[TBL] [Abstract][Full Text] [Related]
19. Correction: Liver injury and rosiglitazone.
Ann Intern Med; 2000 Aug; 133(3):237. PubMed ID: 10906846
[No Abstract] [Full Text] [Related]
20. Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.
Glazer NB; Cheatham WW
BMJ; 2001 Jan; 322(7280):235-6. PubMed ID: 11159615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
